Wang Nana, Li Tiegang, Han Ping
Endocrinology Department, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Emergency Department, Shengjing Hospital of China Medical University, Shenyang 110004, China.
J Diabetes Res. 2016;2016:9261259. doi: 10.1155/2016/9261259. Epub 2015 Nov 10.
In the clinical setting, given the potential adverse effects of thiazolidinediones and biguanides, we often have difficulty in treatment that no other insulin sensitizers are available for use in type 2 diabetic mellitus (T2DM) patients. Tianmai Xiaoke Pian (TMXKP) is a traditional Chinese medicine tablet, which is comprised of chromium picolinate, Tianhuafen, Maidong, and Wuweizi. To understand its mechanism of action on insulin resistance, TMXKP (50 mg/kg orally) was tested in T2DM rats (induced by a high-fat diet and streptozotocin). Eight weeks later, fasting blood glucose (FBG) and oral glucose tolerance tests (OGTT) were performed. Area under the curve (AUC) and homeostatic model assessment of insulin resistance (HOMA-IR) were calculated, and PI3-K/AKT signal pathway-related genes and proteins were tested by reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis in muscle, adipose, and liver tissues, respectively. TMXKP significantly reduced FBG, OGTT, AUC, and HOMA-IR in diabetic rats (P < 0.05). Furthermore, we also observed that TMXKP could significantly decrease IRS-1, IRS-2, PI3-K p85α, and AKT2 gene expression and also IRS-1, IRS-2, PI3-K, AKT2, and p-AKT2 protein expression levels (P < 0.05) in diabetic rats. These findings confirm that TMXKP can alleviate insulin resistance in T2DM rats through the PI3K/AKT pathway. Thus TMXKP appears to be a promising insulin sensitizer.
在临床环境中，鉴于噻唑烷二酮类药物和双胍类药物的潜在不良反应，当没有其他胰岛素增敏剂可用于2型糖尿病（T2DM）患者的治疗时，我们常常面临困难。天麦消渴片（TMXKP）是一种中药片剂，由吡啶甲酸铬、天花粉、麦冬和五味子组成。为了解其对胰岛素抵抗的作用机制，在T2DM大鼠（由高脂饮食和链脲佐菌素诱导）中对TMXKP（50mg/kg口服）进行了测试。八周后，进行空腹血糖（FBG）和口服葡萄糖耐量试验（OGTT）。计算曲线下面积（AUC）和胰岛素抵抗稳态模型评估（HOMA-IR），并分别通过逆转录-聚合酶链反应（RT-PCR）和蛋白质印迹分析在肌肉、脂肪和肝脏组织中检测PI3-K/AKT信号通路相关基因和蛋白质。TMXKP显著降低了糖尿病大鼠的FBG、OGTT、AUC和HOMA-IR（P<0.05）。此外，我们还观察到TMXKP可显著降低糖尿病大鼠中IRS-1、IRS-2、PI3-K p85α和AKT2基因表达以及IRS-1、IRS-2、PI3-K、AKT2和p-AKT2蛋白表达水平（P<0.05）。这些发现证实TMXKP可通过PI3K/AKT途径减轻T2DM大鼠的胰岛素抵抗。因此，TMXKP似乎是一种有前景的胰岛素增敏剂。
